Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 9/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | RHOC | P08134 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9856756 | 0.95 | HMGCR (0.52) | HMGCRNR1I2ABCB11RHOCCYP3A4 | |
| SCHEMBL14283436 | 0.84 | HMGCR (0.60) | HMGCR | |
| SCHEMBL14283405 | 0.84 | HMGCR (0.60) | HMGCR | |
| SCHEMBL14307902 | 0.84 | HMGCR (0.46) | HMGCRNR1I2ABCB11RHOCCYP3A4 | |
| SCHEMBL4980328 | 0.83 | HMGCR (0.56) | HMGCRNR1I2ABCB11RHOCCYP3A4 | |
| SCHEMBL9857125 | 0.81 | HMGCR (0.64) | HMGCRNR1I2ABCB11RHOCCYP3A4 | |
| SCHEMBL9856784 | 0.81 | HMGCR (0.63) | HMGCRNR1I2ABCB11RHOCCYP3A4 | |
| SCHEMBL9856946 | 0.79 | HMGCR (0.61) | HMGCRNR1I2ABCB11RHOCCYP3A4 | |
| SCHEMBL9856801 | 0.79 | HMGCR (0.65) | HMGCR | |
| SCHEMBL9857162 | 0.79 | HMGCR (0.61) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021054-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | NUMERATE, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20070015779-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | NUMERATE, INC. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015779-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | HMGCR, HMGB3, HMGB2 | HMGCR 1/4885NR1I2 734/4885ABCB11 1747/4885 |
| US-20080021054-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | HMGCR, HMGB3, HMGB2 | HMGCR 1/4885NR1I2 733/4885ABCB11 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.